| Trial ID: | L0790 |
| Source ID: | NCT03604016
|
| Associated Drug: |
Besifovir
|
| Title: |
Pilot Study to Assess the Antiviral Activity and Safety of Besifovir Dipivoxil 150mg and L-carnitine 660mg Compared to Tenofovir Alafenamide 25mg in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver
|
| Acronym: |
--
|
| Status: |
Not recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Hepatitis B
|
| Interventions: |
Drug: Besifovir dipivoxil;Drug: L-carnitine;Drug: Tenofovir Alafenamide
|
| Outcome Measures: |
The rate of subjects who showed HBV DNA undetected (less than 116 copies/mL (20 IU/mL)) at the 48 weekThe rate of subjects who showed HBV DNA undetected (less than 116 copies/mL (20 IU/mL)) at the 24 week
|
| Sponsor/Collaborators: |
IlDong Pharmaceutical Co Ltd
|
| Gender: |
All
|
| Age: |
20 Yearsnan
|
| Phases: |
Phase 4
|
| Enrollment: |
76
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
|
| Start Date: |
19/07/2018
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
12 December 2020
|
| Locations: |
--
|
| URL: |
https://clinicaltrials.gov/show/NCT03604016
|
